Information Provided By: 
Fly News Breaks for July 19, 2017
BMRN, SRPT
Jul 19, 2017 | 07:49 EDT
After Sarepta (SRPT) and BioMarin (BMRN) announced a license agreement, SunTrust analyst Edward Nash says the deal resolves a patent dispute between the companies and terminates Sarepta's IP overhang. The analyst says that the deal "effectively provided Sarepta with exclusive rights to BioMarin's DMD patent estate," while the single digit royalty payments to BioMarin are also favorable for Sarepta. He calls the deal "highly positive" for Sarepta and keeps a Buy rating on the stock. .
News For SRPT;BMRN From the Last 2 Days
